LZLiwen Zhang

Liwen Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liwen Zhang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Nan Chen

    Department of Nephrology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

    2 shared publications
  • Weiming Wang

    Department of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China

    2 shared publications
  • Bowen Zhu

    Department of Nephrology, Zhongshan Hospital, Fudan University , Shanghai

    1 shared publication
  • Fangfang Zhou

    Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

    1 shared publication
  • Jian Liu

    Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    1 shared publication
  • Liwen Zhang

    Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Association between long-term exposure to particulate matter 2.5 and the risk of rapid renal function decline: a prospective study from CHARLS

    by Liwen Zhang, Bowen Zhu, Yuxin Nie, Yuanyuan Lu, Xiaoqiang Ding, Yi Fang

    This study investigated the association between particulate matter 2.5 (PM2.5) exposure and rapid renal function decline in Chinese adults aged ≥45. We used data from the China Health and Retirement Longitudinal Study data from 2011 to 2015 (4-year follow-up period). The study outcome was rapid estimated glomerular filtration rate (eGFR) decline, defined as a decrease of ≥33% in eGFR from baseline. The associations between PM2.5 and rapid renal function decline were analyzed by logistic regression models and logistic generalized additive models. Among 4365 participants, higher PM2.5 exposure was linked to increased incidence of rapid eGFR decline (P = .037 for trend). Higher PM2.5 concentrations, older age, a higher baseline eGFR, and elevated hemoglobin A1c and systolic blood pressure levels were identified as independent risk factors for rapid renal function decline (P < .05). Logistic regression demonstrated that higher long-term PM2.5 exposure was associated with rapid eGFR decline (per 10-unit increase; odds ratio (OR) = 1.158 [95% confidence interval (CI) 1.025–1.308], P = .018), particularly in participants with eGFR <90 ml/min/1.73 m2 (per 10-unit increase; OR = 1.298 [95% CI 1.066–1.582], P = .010). Moreover, effect modification indicated that the association between PM2.5 and rapid eGFR decline was significantly stronger in participants with hypertension than in those without hypertension (P = .009 for interaction). An estimated 18.8% of rapid eGFR decline cases were attributable to PM2.5. Furthermore, logistic generalized additive model analysis demonstrated non-linear associations between PM2.5 and rapid eGFR decline, with significant associations observed at higher PM2.5 concentrations (P < .05), especially in individuals with hypertension. Long-term exposure to high PM2.5 is associated with an increased risk of rapid renal function decline, particularly in individuals with low baseline eGFR and hypertension. This finding highlights the need for public health policies to reduce PM2.5 levels and protect vulnerable populations.

  • Open Access

    PPAR gamma and PGC‐1alpha activators protect against diabetic nephropathy by suppressing the inflammation and NF‐kappaB activation

    by Siyi Huang, Yuanmeng Jin, Liwen Zhang, Ying Zhou, Nan Chen, Weiming Wang

    Aim: Inflammation plays a critical role in the progression of diabetic nephropathy. Peroxisome proliferator‐activated receptor gamma (PPARγ) and its coactivator PPARγ coactivator‐1 alpha (PGC‐1α) enhance mitochondrial biogenesis and cellular energy metabolism but inhibit inflammation. However, the molecular mechanism through which these two proteins cooperate in the kidney remains unclear. The aim of the present study was to investigate this mechanism.Methods: HK‐2 human proximal tubular cells were stimulated by inflammatory factors, the expression of PPARγ and PGC‐1α were determined via reverse transcription‐quantitative polymerase chain reaction (PCR) and western blotting (WB), and DNA binding capacity was measured by an EMSA. Furthermore, db/db mice were used to establish a diabetic nephropathy model and were administered PPARγ and PGC‐1α activators. Kidney injury was evaluated microscopically, and the inflammatory response was assessed via WB, immunohistochemistry and immunofluorescence staining. Besides, HK‐2 cells were stimulated by high glucose and inflammatory factors with and without ZLN005 treatment, the expression of PPARγ, PGC‐1α, p‐p65 and p65 were determined via qPCR and WB.Results: Our results revealed that both TNF‐α and IL‐1β significantly decreased PPARγ and PGC‐1 expression in vitro. Cytokines obviously decreased PPARγ DNA binding capacity. Moreover, we detected rapid activation of the NF‐κB pathway in the presence of TNF‐α or IL‐1β. PPARγ and PGC‐1α activators effectively protected against diabetic nephropathy and suppressed NF‐κB expression both in db/db mice and HK‐2 cells.Conclusion: PPARγ and its coactivator PGC‐1α actively participate in protecting against renal inflammation by regulating the NF‐κB pathway, which highlights their potential as therapeutic targets for renal diseases.


  • Open Access

    P-selectin blockade ameliorates lupus nephritis in MRL/lpr mice through improving renal hypoxia and evaluation using BOLD-MRI

    by Liwen Zhang, Sheng Chen, Yan Liu, Xueqin Xu, Qianying Zhang, Shuxin Shao, Weiming Wang, Xiao Li

    Background: Lupus nephritis is one of the most common and severe complications of systemic lupus erythematosus, of which poor prognosis is indicated by aggravated renal hypoxia and tubulointerstitial fibrosis. Cell adhesion molecules play a key role in the progression of lupus nephritis tubulointerstitial lesion, including P-selectin, which mediates the rolling of leukocytes and subsequent adhesion and infiltration and then initiates the inflammatory immune response and ischemia and hypoxia injury. However, the effects and mechanisms of P-selectin in lupus nephritis remain to be investigated, and a noninvasive measurement of lupus nephritis tubulointerstitial hypoxia and fibrosis remains to be explored. Methods: Thirty-four MRL/lpr mice were randomly divided into the following three groups: MRL/lpr, saline, and anti-P-selectin, which consisted of no treatment, treatment with normal saline, and treatment with anti-P-selectin monoclonal antibody (mAb) from 12 to 16 weeks of age, respectively. Ten male C57BL/6 mice of the same age served as normal controls. 24-h urinary protein, urinary albumin–creatinine ratio, and periodic acid–Schiff were used to assess kidney damage; Western blot or immunohistochemical staining of the hypoxia probe Hypoxyprobe™-1, hypoxia-inducible factor 1α (HIF-1α), and CD31 were used to evaluate hypoxia in renal tissue; and NADPH oxidase subunit gp91phox and p22phox were used to examine renal oxidative stress. The correlation between kidney injury and blood oxygen level–dependent magnetic resonance imaging (BOLD-MRI) was calculated to assess the clinical value of BOLD-MRI. Results: P-selectin is upregulated in lupus nephritis. Blocking P-selectin with mAb alleviated renal tubulointerstitial fibrosis, renal hypoxia, and peritubular capillary loss, without alteration of the levels of lupus activity indicators, anti-dsDNA antibody, or complement C3. BOLD-MRI showed that the reduced R2* values in the renal cortex and medulla of lupus mice were increased when treated with anti-P-selectin mAb as compared with those treated with normal saline, which were negatively correlated with Hypoxyprobe™-1 hypoxia probe and the expression of HIF-1α. Conclusions: Early intervention of lupus nephritis with anti-P-selectin mAb can significantly improve the hypoxic state of the kidney and reduce the severity of tubulointerstitial lesions. BOLD-MRI techniques are noninvasive and can dynamically evaluate the changes in renal lesions and intrarenal oxygenation levels before and after treatment in lupus nephritis.


  • Open Access

    Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone

    by Liwen Zhang, Ying Zhou, Fangfang Zhou, Xialian Yu, Jian Liu, Yunzi Liu, Yufei Zhu, Weiming Wang, Nan Chen

    Diabetic nephropathy (DN) is characterized by metabolic disorder and inflammation. However, the regulatory effects that long noncoding RNAs (lncRNAs) have on the pathogenesis of DN and on the efficacy of rosiglitazone treatment have yet to be clearly defined. Herein, we performed unbiased RNA sequencing to characterize the transcriptomic profiles in db/db diabetic mouse model with or without rosiglitazone treatment that served to improve the phenotypes of DN. Moreover, RNA‐seq profiling revealed that the development of DN caused an upregulation in the expression of 1176 mRNAs and a downregulation in the expression of 1010 mRNAs compared to controls, with the expression of 251 mRNAs being returned to normal following treatment with rosiglitazone. Further, 88 upregulated and 68 downregulated lncRNAs were identified in db/db mice compared to controls, 10 of which had their normal expression restored following treatment with rosiglitazone. Bioinformatic analysis revealed that the primary pathways involved in the pathogenesis of DN, and subsequently in the therapeutic effects of PPARγ, are related to inflammatory and metabolic processes. From bioinformatics analysis, lncRNA‐AI838599 emerged as a novel molecular mechanism for rosiglitazone treatment in DN through TNFα‐NFκb pathway. These findings may indicate a new molecular regulatory approach for the development of DN therapeutic agents.